Obesity Jab Drug Fails To Slow Alzheimer’s
Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer’s — despite initial hopes that it might help against dementia. From a report: Researchers began two large trials involving more than 3,800 people after reports the medicine was having an impact in the real world. But […]
New Moms’ GLP-1 Prescriptions Jumped After Wegovy Approval
(MedPage Today) — Prescriptions for GLP-1 receptor agonists increased among postpartum women once semaglutide (Ozempic, Wegovy) was approved for weight loss, a Danish epidemiological study found. In the first quarter of 2018, there were less…
Novo Nordisk has a lot of challenges next year and beyond, says Guggenheim’s Seamus Fernandez
Seamus Fernandez, Guggenheim biotech analyst, joins ‘Power Lunch’ to discuss Novo Nordisk’s latest earnings results, if there’s a clear winner in the GLP-1 space and much more.
Passing on the pie? Thanksgiving takes a turn in the Ozempic er
Many people using GLP-1 weight loss drugs are seeing big changes during the holiday season. These medicines make people feel full faster, so Thanksgiving meals may feel different this year. Experts say families should be kind, avoid comments about eating or weight, and support loved ones using GLP-1 drugs as they adjust to new habits […]
This Healthcare Company Just Touched $1 Trillion in Market Cap. Should You Invest $1,000?
Key Points Eli Lilly has a dominant share of the huge and expanding GLP-1 drug market. Its GLP-1 drugs will soon be partially covered by Medicare. Lilly is close to releasing a pill form of its best-selling drug. 10 stocks we like better than Eli Lilly › Just a handful of companies have entered the […]
Monday links: speculating on a bubble
Strategy Investor behavior matters a lot when it comes to investing in ‘oddball funds.’ (morningstar.com) Bubbles are only obvious in hindsight. (ritholtz.com) Crypto How the Trump family fortune has been affected by the crypto downturn. (bloomberg.com) The Grayscale Dogecoin Trust ETF ($GDOG) is now live. (theblock.co) Pharma Moderna ($MRNA) is the most shorted stock in […]
Evoke Phase 3 Oral Semaglutide Trials Did Not Demonstrate a Statistically Significant Reduction in Alzheimer’s Disease Progression
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were…
Lessons Learned From Antiobesity Medication Withdrawal Trials
The use of glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, such as tirzepatide, continues to climb amidst patient demand and a growing set of clinical indications for treatment. As specialists and primary care clinicians adopt these medications, they need to be well-versed in the clinical benefits and risks of both starting and […]
Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations, preterm birth, gestational diabetes, and preeclampsia, which can have significant long-term consequences for mother and infant. By enabling women to begin pregnancy at a lower […]
Increasing Postpartum Use of GLP-1 Receptor Agonists
This study uses data from the Danish Medical Birth Register to examine postpartum use of glucagon-like peptide 1 receptor agonists.